Targeted Oncology Staff

FIT-001 updates show darlifarnib plus cabozantinib drives 33% to 50% responses and 13‑month PFS in pretreated patients with cabozantinib-naive ccRCC.

Experts break down second-line CAR T for relapsed DLBCL—who qualifies, what to expect, and why logistics still block access.

During a live event, Ruta Rao, MD, and participants discussed how the redefined HER2 spectrum is reshaping first antibody-drug conjugate selection in HR+/HER2– metastatic breast cancer.

FDA clears zidesamtinib for previously treated ROS1-positive metastatic NSCLC, showing 44% responses, CNS activity, and manageable safety in ARROS-1 trial.

Explore second-line options after ICI failure in metastatic ccRCC, featuring TiNivo-2 insights and tivozanib’s tolerability and PFS.

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung cancer.

Phase 2 data show safusidenib drives deepening responses and durable control in IDH1‑mutant grade 2 glioma, prompting new trials for earlier and post‑vorasidenib use.

During a live event, Matthew Rettig, MD, examined treatment options for a patient who had received prior doublet therapy for metastatic castration-resistant prostate cancer.

A trend toward improvement in overall survival (OS) with pembrolizumab was observed; however, the OS data are not mature.

Oncologists debate BTK inhibitor choices in relapsed CLL, exploring when MRD testing matters, toxicity management, and insurance hurdles.

During a live event, Sapna Patel, MD, and participants discussed second-line treatment selection for a patient with mucosal melanoma and considered how the limited available data shape that choice.

During a live event, Prerna Mewawalla, MD, discussed the choice between bispecific antibody therapy and CAR T-cell therapy in myeloma as both therapies have been introduced earlier in sequence.

Pegfilgrastim-pccg now carries the same indications as its reference product, Neulasta.

During a live event, Kristen M. Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.

During a live event, Bruna Pellini, MD, and participants discussed treatment sequencing and post progression management in patients with ROS1-positive advanced non–small cell lung cancer.

During a live event, Brittany Siontis, MD, discussed a case of a 50-year-old patient with an actively growing desmoid tumor.

During a live event, Andrew Brunner, MD, and participants discussed second-line therapy selection in lower-risk MDS following ESA failure.

During a live event, Sikander Ailawadhi, MD, and participants discussed treatment selection for a patient with heavily pretreated multiple myeloma who was not a candidate for CAR T-cell therapy and had exhausted both BCMA and GPRC5D-targeted bispecific options.

ASCO 2026 data reshapes lung cancer care, highlighting durable ALK control, new EGFR options, bispecific first-line gains, and SCLC progress.

Experts weigh leading IO/TKI combos for advanced RCC, comparing trials, toxicities, metastasis sites, and CNS strategy to personalize first-line care.

ASCO 2026 highlights, FDA moves, and AI mammography sharpen breast cancer care—ADCs, ctDNA, and de-escalation reshape treatment and screening debates.

FDA oncology Q2 2026 brings major breast, prostate and kidney cancer approvals, split ODAC votes, and RP1 melanoma setback heading into Q3.

During a live event, Syed Abbas Ali, MBBS, and participants discussed treatment selection for a patient who has not yet received BCMA-targeted therapy after a second relapse of multiple myeloma.

June 2026 FDA oncology updates bring major breast cancer shifts plus new prostate and kidney approvals, while melanoma and NET imaging decisions loom.

During a live event, Zev Wainberg, MD, and participants discussed frontline immunotherapy selection in advanced HER2-negative gastrointestinal cancers.

Catherine Coombs, MD and oncologists weigh frontline CLL therapy choices, balancing BTK inhibitors vs fixed-duration venetoclax combinations as age, comorbidities, and new trial data guide decisions.

Q3 2026 FDA oncology verdicts loom for ADCs and targeted drugs in breast, melanoma, gastric, blood, and lung cancers.

Explore how GI and pancreatic NET sites shape symptoms and survival, plus NCCN-backed therapies from somatostatin analogs to PRRT and cabozantinib.

During a live event, Matthew Rettig, MD, and participating oncologists discussed a case of a 74-year-old man with metastatic hormone-sensitive prostate cancer.

Experts debate tivozanib’s durable responses and tolerability after immunotherapy in metastatic RCC, shaping smarter VEGFR-TKI sequencing.